首页|奈达铂联合多西他赛在非小细胞肺癌合并肺结核患者中的应用效果

奈达铂联合多西他赛在非小细胞肺癌合并肺结核患者中的应用效果

Application effect of nedaplatin combined with docetaxel in patients with non-small cell lung cancer complicated with pulmonary tuberculosis

扫码查看
目的 探讨奈达铂联合多西他赛在非小细胞肺癌(NSCLC)合并肺结核患者中的应用效果.方法 选取60例NSCLC合并肺结核患者,均接受抗结核治疗,根据治疗方法的不同分为奈达铂组(n=30,奈达铂+多西他赛治疗)和顺铂组(n=30,顺铂+多西他赛治疗).比较两组患者的临床疗效、炎性反应指标[白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、γ干扰素(IFN-γ)、C反应蛋白(CRP)]、免疫功能指标[CD4+/CD8+、辅助性T细胞(Th)1/Th2].结果 奈达铂组患者的治疗总有效率为73.33%,高于顺铂组患者的43.33%,差异有统计学意义(P﹤0.05).治疗后,两组患者IL-2、IFN-γ水平均高于本组治疗前,IL-6、CRP水平均低于本组治疗前,奈达铂组患者IL-2、IFN-γ水平均高于顺铂组,IL-6、CRP水平均低于顺铂组,差异均有统计学意义(P﹤0.05).治疗后,两组患者CD4+/CD8+、Th1/Th2均高于本组治疗前,奈达铂组患者CD4+/CD8+、Th1/Th2均高于顺铂组,差异均有统计学意义(P﹤0.05).结论 奈达铂联合多西他赛及抗结核方案治疗NSCLC合并肺结核患者的临床疗效较好,能够提高患者的免疫功能,减轻炎性反应.
Objective To investigate the application effect of nedaplatin combined with docetaxel in patients with non-small cell lung cancer(NSCLC)complicated with pulmonary tuberculosis.Method A total of 60 patients with NSCLC complicated with pulmonary tuberculosis were selected,and all of them received anti-tuberculosis treatment.They were divided into nedaplatin group(n=30,treated with nedaplatin+docetaxel)and the cisplatin group(n=30,treat-ed with cisplatin+docetaxel)according to different treatment methods.The clinical efficacy,inflammatory response indi-cators[interleukin-2(IL-2),interleukin-6(IL-6),interferon-γ(IFN-γ),C-reactive protein(CRP)],immune function indica-tors[CD4+/CD8+,helper T cell(Th)1/Th2]were compared between the two groups.Result The total effective rate of treatment in nedaplatin group was 73.33%,which was higher than 43.33%in cisplatin group,and the difference was statis-tically significant(P<0.05).After treatment,the levels of IL-2,IFN-γ in both groups were higher than those before treat-ment,while the levels of IL-6,CRP were lower than those before treatment,the levels of IL-2,IFN-γ in nedaplatin group were higher than those in cisplatin group,while the levels of IL-6,CRP were lower than those in cisplatin group,and the differences were statistically significant(P<0.05).After treatment,the CD4+/CD8+,Th1/Th2 in both groups were higher than those before treatment,the CD4+/CD8+,Th1/Th2 in nedaplatin group were higher than those in cisplatin group,and the differences were statistically significant(P<0.05).Conclusion The nedaplatin combined with docetaxel and anti-tu-berculosis regimen has good clinical efficacy in treating patients with NSCLC complicated with pulmonary tuberculosis.It can improve immune function and alleviate inflammatory reactions.

non-small cell lung cancerpulmonary tuberculosisnedaplatincisplatindocetaxel

贾会英、朱华强

展开 >

濮阳市第五人民医院 结核一科,河南 濮阳 457100

濮阳市第五人民医院 肿瘤科,河南 濮阳 457100

非小细胞肺癌 肺结核 奈达铂 顺铂 多西他赛

2024

癌症进展
中国医学科学院,北京协和医学院

癌症进展

影响因子:1.004
ISSN:1672-1535
年,卷(期):2024.22(22)